IN 1967 the National Heart and Lung Institute organized a multi-institutional controlled clinical trial to evaluate thrombolytic agents in the treatment of pulmonary embolism. ' The results of the first phase of that study (The Urokinase Pulmonary Embolism Trial) showed that 12 hours of urokinase compared to heparin and oral anticoagulants alone increased the resolution rate of pulmonary thromboemboli, especially massive emboli, as judged by arteriography, hemodynamics, and lung scanning, assessed within 24 hours of therapy.2 3 4 Serial lung scanning revealed that these differences in embolus resolution rates decreased when assessed at 14 days. massive emboli group where statistical significance is attained. The hemodynamic changes are inconsistent. In those patients in whom both pulmonary artery pressure and cardiac index were measured, there were no significant differences. Twenty-four hours of urokinase may be superior to 24 hours of streptokinase, but any difference appears small.
Throughout Phase I and Phase II, standardized dosage schedules of both urokinase and streptokinase were used. Although laboratory studies indicated successful activation of the endogenous plasminogenplasmin fibrinolytic system in nearly 100% of the patients, different dosage schedules may produce different therapeutic results.
Contraindications to thrombolytic agents were observed as were restrictions on patients with recent streptococcal infections. Under these circumstances, the allergic, pyrogenic, and bleeding complications were controllable. About a third of the bleeding episodes occurred after the termination of the thrombolytic infusion but during therapy with standard anticoagulants.
Analysis of these trials shows no reduction in mortality with the use of thrombolytic agents. A trial designed with mortality as the main end point would require a prohibitively large patient sample. However, a major physiologic benefit, especially in patients with massive embolism, was observed. These agents have potential, therefore, in the severely ill patients with massive embolism and in patients with massive or submassive embolism who also have diminished cardiac reserve. When standard anticoagulation has been chosen as the initial treatment in a patient with pulmonary embolism, thrombolytic therapy should be considered if the clinical response is unsatisfactory. Both urokinase and streptokinase have promise as useful alternatives to heparin and oral anticoagulants and the hazardous procedure of embolectomy.
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